Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 4Active not recruiting 4Unknown 2Withdrawn 1Recruiting 1Enrolling by invitation 1

Sponsor Class

INDUSTRY 2OTHER 1NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 4Breast 2Gynecologic 1Gastrointestinal 1

Conditions

Breast Neoplasms 20Ovarian Neoplasms 19Fallopian Tube Neoplasms 9Prostatic Neoplasms 7Triple Negative Breast Neoplasms 6Neoplasm Metastasis 6Small Cell Lung Carcinoma 4Pancreatic Neoplasms 4Metastatic Castration-resistant Prostate Cancer 4Squamous Cell Carcinoma of Head and Neck 3Lung Neoplasms 3Glioma 3Endometrial Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Uterine Cervical Neoplasms 2Stomach Neoplasms 2Solid Tumors 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Osteosarcoma 2Neoplasms 2Glioblastoma 2Cholangiocarcinoma 2Carcinosarcoma 2Carcinoma, Endometrioid 2Xanthogranuloma, Juvenile 1Wilms Tumor 1Urinary Bladder Neoplasms 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1

Interventions

Carboplatin 15durvalumab 14Etoposide 14pembrolizumab 9atezolizumab 9Cisplatin 9Topotecan 8Nivolumab 7Specimen Handling 6olaparib 4berzosertib 4Temozolomide 4Magnetic Resonance Spectroscopy 4AMG 757 4tremelimumab 3Radiotherapy 3Radiosurgery 3PM 01183 3Ipilimumab 3Docetaxel 3Biopsy 3niraparib 2lenvatinib 2cabozantinib 2Platinum 2Irinotecan 2Fulvestrant 2veliparib 1tislelizumab 1tazemetostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Active not recruiting × Small Cell Lung Carcinoma × olaparib × Clear all
NCT04624204 2026-05-26

MK 7339-013

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
672 enrolled
Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Small Cell Lung Carcinoma

NCT02498613 2026-05-01

A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors

National Cancer Institute (NCI)

Phase 2 Active not recruiting
122 enrolled 16 charts
BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT02734004 2026-04-20

MEDIOLA

AstraZeneca

Phase 1/2 Active not recruiting
264 enrolled 32 charts
BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Small Cell Lung Carcinoma

NCT03923270 2026-04-01

Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Active not recruiting
25 enrolled
Thoracic

Lung Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡